Feedback / Questions
Enhertu (fam-trastuzumab deruxtecan-nxki) - Daiichi Sankyo, AstraZeneca
rilvegostomig (AZD2936) - AstraZeneca
Keytruda (pembrolizumab) - Merck (MSD)
https://www.daiichisankyo.com/files/news/pressrelease/pdf/202506/20250609_E.pdf
Jun 9, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next